全球 β 地中海贫血市场 – 行业趋势和 2030 年预测

β-地中海贫血市场分析和规模

地中海贫血患病率的上升将成为推动市场增长的主要驱动力。影响全球β-地中海贫血市场增长率的另一个重要因素是医疗保健支出的上升。此外，医疗技术的进步、公共和私人组织为传播意识而采取的举措不断增加以及政府资金的增加都是扩大全球β-地中海贫血市场的因素。此外，高可支配收入和生活方式的改变将导致全球β-地中海贫血市场的扩张。

 Data Bridge Market Research 分析称，全球 β-地中海贫血市场在 2022 年为 83.2 亿美元，预计到 2030 年将达到 112.2 亿美元，预计在 2023 年至 2030 年的预测期内复合年增长率为 8.0%。由于地中海贫血的患病率不断上升，“轻型 β-地中海贫血”在全球 β-地中海贫血市场类型细分市场中占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。

β-地中海贫血市场范围和细分

市场定义

β-地中海贫血是一种血液病。这是一种遗传性疾病，患者身体产生的血红蛋白比正常情况下少。血红蛋白是指存在于红细胞中的含铁蛋白质，它负责将氧气输送到全身的细胞。血红蛋白水平低将进一步导致身体各个部位缺氧。β-地中海贫血是由于 HBB 基因突变而引起的。HBB 基因传递产生一种名为 β-珠蛋白的蛋白质的指令。这种疾病的特征包括贫血、呼吸短促、疲倦、心跳加速、情绪不稳定、黄疸和生长缓慢等。地中海贫血是 β-地中海贫血的另一个术语。

全球β地中海贫血市场动态

驱动程序

• 地中海贫血患病率上升

地中海贫血患病率的上升是全球β-地中海贫血市场的重要推动力。地中海贫血是一种遗传性血液疾病，特征是血红蛋白生成异常，影响着全世界大量人群。地中海贫血患病率的上升导致越来越多的患者需要医疗干预，包括输血、螯合疗法以及 基因疗法和干细胞移植等潜在治愈性治疗。患者数量的增加推动了全球β-地中海贫血市场对诊断测试、治疗和支持性护理 的需求，从而为创新治疗方案的研究、开发和商业化创造了机会。

• Rising Healthcare Expenditure

Rising healthcare expenditure acts as a significant driver in the global beta-thalassemia market. The complex nature of thalassemia requires comprehensive medical management, including regular blood transfusions, iron chelation therapy, and potential curative treatments. As the prevalence of thalassemia increases, healthcare expenditure on diagnostic tests, treatments, and supportive care rises accordingly. This drives the demand for advanced medical technologies, pharmaceuticals, and specialized healthcare services. Consequently, healthcare providers, research institutions, and pharmaceutical companies invest in developing innovative therapies, gene therapies, and supportive care options, driving market growth and contributing to improved outcomes for patients with beta-thalassemia.

Opportunities

• Increasing Advancements in Medical Technology

Advancements in medical technology present significant opportunities in the global beta-thalassemia market. Innovations in diagnostic tools, such as genetic testing and molecular techniques, enable early and accurate diagnosis of thalassemia. In addition, advancements in medical devices, such as portable infusion pumps for chelation therapy and implantable devices for monitoring iron levels, enhance treatment convenience and patient outcomes. Furthermore, gene therapy and stem cell transplantation technologies hold promising potential for curative treatments in beta-thalassemia. These advancements not only improve patient care but also create opportunities for research, development, and commercialization of cutting-edge therapies and medical devices in the global beta-thalassemia market.

• Increasing Demand for Precision Medicines

Advancements in genomics and precision medicine offer opportunities for tailoring treatments to individual patients based on their genetic profiles. This can potentially lead to more effective and targeted therapies for beta thalassemia.

Restraints/ Challenges

• Strict Regulations and Guidelines

The development and approval of new therapies for beta thalassemia can be a lengthy and expensive process due to stringent regulatory requirements. Companies may face hurdles in getting their products to market.

• Limited Treatment Options

There was a limited number of approved treatments for beta thalassemia, primarily involving blood transfusions and iron chelation therapy. The development of new and more effective treatments may face challenges related to research and regulatory approvals.

• High Cost of Treatment

The high cost associated with the treatment of beta-thalassemia poses a significant challenge in the global market. The complex management of beta-thalassemia, including regular blood transfusions, chelation therapy, and potentially curative treatments, involves substantial healthcare expenditures. The cost of specialized medications, supportive care, diagnostic tests, and lifelong management can place a financial burden on patients, healthcare systems, and payers. This challenge limits accessibility to optimal care, particularly in regions with limited healthcare resources and individuals without adequate insurance coverage. Addressing the high cost of treatment is crucial to ensure equitable access and improve outcomes for patients with beta-thalassemia worldwide.

This global beta-thalassemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, and technological innovations in the market. To gain more info on the global beta-thalassemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.

Global Beta Thalassemia Market Scope

The global beta-thalassemia market is segmented on the basis of type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.   

Type

• Beta Thalassemia Minor
• Beta Thalassemia Intermedia 
• Beta Thalassemia Major

Treatment

• Iron Chelating Drugs
• Erythroid Maturation Agents
• Stem Cell Therapy
• Blood transfusion
• Others

 Diagnosis

• Complete Blood Count (CBC)
• Hemoglobin Electrophoresis with Hemoglobin F and A2 Quantitation
• Others

Symptoms

• Shortness of Breath
• Tiredness
• Fast Heartbeat
• Moodiness
• Jaundice
• Slow Growth
• Others

Dosage

• Injection
• Tablets
• Others

 Route of Administration

• Oral
• Intravenous
• Others

End-Users

• Hospital
• Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Beta Thalassemia Market Regional Analysis/Insights

The global beta-thalassemia market is analyzed and market size insights and trends are provided by country, type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.     

The countries covered in the global beta-thalassemia market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.   

North America dominates the global beta-thalassemia market because of the increasing healthcare initiatives, the strong presence of major players in the market, increasing cases of thalassemia and rising number of research activities in this region.  Asia-Pacific is expected to witness significant growth in the global beta-thalassemia market during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.  

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Global beta-thalassemia market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for global beta-thalassemia market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global beta-thalassemia market. The data is available for historic period 2015 to 2020.

Competitive Landscape and Global Beta-Thalassemia Market Share Analysis

The global beta-thalassemia market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the global beta-thalassemia market.   

Some of the major players operating in the global beta-thalassemia market are:  

• bluebird bio, Inc. (U.S.)
• Protagonist Therapeutics Inc.（美国）
• Agios, Inc.（美国）
• Ionis Pharmaceuticals（美国）
• Vifor Pharma 集团（瑞士）
• Sangamo Therapeutics（美国）
• CRISPR Therapeutics（瑞士）

SKU-67632